These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23686525)

  • 21. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
    Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
    Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
    Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
    Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.
    Jentzsch M; Bill M; Nicolet D; Leiblein S; Schubert K; Pless M; Bergmann U; Wildenberger K; Schuhmann L; Cross M; Pönisch W; Franke GN; Vucinic V; Lange T; Behre G; Mrózek K; Bloomfield CD; Niederwieser D; Schwind S
    Am J Hematol; 2017 Apr; 92(4):388-396. PubMed ID: 28133783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells.
    Terstappen LW; Safford M; Unterhalt M; Könemann S; Zurlutter K; Piechotka K; Drescher M; Aul C; Büchner T; Hiddemann W
    Leukemia; 1992 Oct; 6(10):993-1000. PubMed ID: 1383649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of embryonic stem cell markers in acute myeloid leukemia.
    Picot T; Aanei CM; Fayard A; Flandrin-Gresta P; Tondeur S; Gouttenoire M; Tavernier-Tardy E; Wattel E; Guyotat D; Campos L
    Tumour Biol; 2017 Jul; 39(7):1010428317716629. PubMed ID: 28718379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma.
    Yen CC; Chen SC; Hung GY; Wu PK; Chua WY; Lin YC; Yen CH; Chen YC; Wang JY; Yang MH; Chao Y; Chang MC; Chen WM
    Int J Oncol; 2019 Oct; 55(4):938-948. PubMed ID: 31485600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
    Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
    Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
    Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
    Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
    Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
    Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
    [No Abstract]   [Full Text] [Related]  

  • 33. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.
    Kim YR; Eom JI; Kim SJ; Jeung HK; Cheong JW; Kim JS; Min YH
    J Pharmacol Exp Ther; 2010 Nov; 335(2):389-400. PubMed ID: 20699435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
    Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
    Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway.
    Zhang Y; Chen HX; Zhou SY; Wang SX; Zheng K; Xu DD; Liu YT; Wang XY; Wang X; Yan HZ; Zhang L; Liu QY; Chen WQ; Wang YF
    Mol Cancer; 2015 Mar; 14():56. PubMed ID: 25890196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
    Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
    Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
    Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
    J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
    Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
    Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Aurora kinase A suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo.
    Tanaka H; Nakashiro K; Iwamoto K; Tokuzen N; Fujita Y; Shirakawa R; Oka R; Goda H; Hamakawa H
    Oral Oncol; 2013 Jun; 49(6):551-9. PubMed ID: 23481312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.